Overview Dividends

(RDY) Dr. Reddy’s Laboratories - Ratings and Ratios

Exchange: NYSE • Country: India • Currency: USD • Type: Common Stock • ISIN: US2561352038

Generics, APIs, Biologics, Oncotherapies, Formulations

EPS (Earnings per Share)

EPS (Earnings per Share) of RDY over the last years for every Quarter: "2020-09": 0.62, "2020-12": 0.02, "2021-03": 0.46, "2021-06": 0.47, "2021-09": 0.81, "2021-12": 0.57, "2022-03": 0.07, "2022-06": 0.9, "2022-09": 0.82, "2022-12": 0.91, "2023-03": 0.7, "2023-06": 0.2056, "2023-09": 88.91, "2023-12": 82.81, "2024-03": 78.35, "2024-06": 83.46, "2024-09": 15.83, "2024-12": 16.94, "2025-03": 19.11, "2025-06": 17.02, "2025-09": 0.1972,
EPS CAGR: -42.65%
EPS Trend: 16.1%
Last SUE: -2.34σ
Qual. Beats: 0

Revenue

Revenue of RDY over the last years for every Quarter: 2020-09: 658.385076, 2020-12: 49296, 2021-03: 648.674376, 2021-06: 49194, 2021-09: 777.856169, 2021-12: 53197, 2022-03: 722.586456, 2022-06: 52154, 2022-09: 790.107771, 2022-12: 67700, 2023-03: 765.596, 2023-06: 67384, 2023-09: 832.199025, 2023-12: 72148, 2024-03: 70830, 2024-06: 76727, 2024-09: 80162, 2024-12: 83586, 2025-03: 85060, 2025-06: 85452, 2025-09: 88051,
Revenue CAGR: 10.03%
Revenue Trend: 49.8%
Last SUE: 0.02σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 23.9%
Value at Risk 5%th 37.0%
Relative Tail Risk -5.85%
Reward TTM
Sharpe Ratio -0.12
Alpha -12.43
Character TTM
Hurst Exponent 0.560
Beta 0.417
Beta Downside 0.462
Drawdowns 3y
Max DD 26.61%
Mean DD 8.50%
Median DD 7.41%

Description: RDY Dr. Reddy’s Laboratories October 31, 2025

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical firm headquartered in Hyderabad, India, operating across North America, Europe, India, Russia and other markets. It segments its business into Global Generics (prescription and OTC drugs plus biologics), PSAI (active pharmaceutical ingredients, intermediates and contract research) and Others (oncology, inflammation and differentiated formulations). The product portfolio spans gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, urology, nephrology, vaccines and pain management.

Key recent metrics: FY 2023 revenue reached $3.4 billion, up ~7 % YoY, driven by strong generic launches in the U.S. and expanding API sales in Europe; R&D intensity was ~13 % of sales, reflecting a pipeline of 12 late-stage oncology candidates. A material sector driver is the U.S. “generic drug pricing reform” debate, which can compress margins but also creates opportunities for cost-efficient manufacturers like Dr. Reddy’s that have a diversified API business to offset pricing pressure.

For a deeper, data-rich assessment of RDY’s valuation dynamics, you may find it worthwhile to explore the analyst tools on ValueRay, where detailed financial models and scenario analyses are publicly available.

RDY Stock Overview

Market Cap in USD 11,635m
Sub-Industry Pharmaceuticals
IPO / Inception 2001-04-11
Return 12m vs S&P 500 -15.3%
Analyst Rating 3.50 of 5

RDY Dividends

Metric Value
Dividend Yield 0.67%
Yield on Cost 5y 0.81%
Yield CAGR 5y 27.97%
Payout Consistency 86.0%
Payout Ratio 0.2%

RDY Growth Ratios

Metric Value
CAGR 3y 10.18%
CAGR/Max DD Calmar Ratio 0.38
CAGR/Mean DD Pain Ratio 1.20
Current Volume 825.4k
Average Volume 1002k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (58.62b TTM) > 0 and > 6% of Revenue (6% = 20.53b TTM)
FCFTA 0.03 (>2.0%) and ΔFCFTA 2.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 37.58% (prev 39.63%; Δ -2.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 58.82b > Net Income 58.62b (YES >=105%, WARN >=100%)
Net Debt (48.63b) to EBITDA (98.49b) ratio: 0.49 <= 3.0 (WARN <= 3.5)
Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (833.0m) change vs 12m ago -0.13% (target <= -2.0% for YES)
Gross Margin 56.43% (prev 59.29%; Δ -2.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 67.89% (prev 64.36%; Δ 3.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 24.73 (EBITDA TTM 98.49b / Interest Expense TTM 3.21b) >= 6 (WARN >= 3)

Altman Z'' 6.64

(A) 0.24 = (Total Current Assets 279.52b - Total Current Liabilities 150.93b) / Total Assets 542.00b
(B) 0.62 = Retained Earnings (Balance) 337.68b / Total Assets 542.00b
(C) 0.16 = EBIT TTM 79.40b / Avg Total Assets 503.98b
(D) 1.90 = Book Value of Equity 342.50b / Total Liabilities 179.92b
Total Rating: 6.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.13

1. Piotroski 7.0pt
2. FCF Yield 1.80%
3. FCF Margin 5.40%
4. Debt/Equity 0.16
5. Debt/Ebitda 0.49
6. ROIC - WACC (= 8.88)%
7. RoE 17.25%
8. Rev. Trend 49.78%
9. EPS Trend 16.15%

What is the price of RDY shares?

As of November 25, 2025, the stock is trading at USD 13.66 with a total of 825,448 shares traded.
Over the past week, the price has changed by -2.15%, over one month by -6.31%, over three months by -5.53% and over the past year by -4.01%.

Is RDY a buy, sell or hold?

Dr. Reddy’s Laboratories has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold RDY.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the RDY price?

Issuer Target Up/Down from current
Wallstreet Target Price 14.8 8.1%
Analysts Target Price 14.8 8.1%
ValueRay Target Price 13.9 1.5%

RDY Fundamental Data Overview November 25, 2025

Market Cap INR = 1036.68b (11.63b USD * 89.104 USD.INR)
P/E Trailing = 17.6076
P/E Forward = 20.0401
P/S = 0.034
P/B = 2.8585
P/EG = 3.3984
Beta = 0.358
Revenue TTM = 342.15b INR
EBIT TTM = 79.40b INR
EBITDA TTM = 98.49b INR
Long Term Debt = 3.80b INR (from longTermDebt, last fiscal year)
Short Term Debt = 46.90b INR (from shortTermDebt, last quarter)
Debt = 58.54b INR (from shortLongTermDebtTotal, last quarter)
Net Debt = 48.63b INR (from netDebt column, last quarter)
Enterprise Value = 1025.41b INR (1036.68b + Debt 58.54b - CCE 69.81b)
Interest Coverage Ratio = 24.73 (Ebit TTM 79.40b / Interest Expense TTM 3.21b)
FCF Yield = 1.80% (FCF TTM 18.47b / Enterprise Value 1025.41b)
FCF Margin = 5.40% (FCF TTM 18.47b / Revenue TTM 342.15b)
Net Margin = 17.13% (Net Income TTM 58.62b / Revenue TTM 342.15b)
Gross Margin = 56.43% ((Revenue TTM 342.15b - Cost of Revenue TTM 149.07b) / Revenue TTM)
Gross Margin QoQ = 54.67% (prev 56.91%)
Tobins Q-Ratio = 1.89 (Enterprise Value 1025.41b / Total Assets 542.00b)
Interest Expense / Debt = 1.55% (Interest Expense 907.0m / Debt 58.54b)
Taxrate = 22.25% (4.08b / 18.35b)
NOPAT = 61.74b (EBIT 79.40b * (1 - 22.25%))
Current Ratio = 1.85 (Total Current Assets 279.52b / Total Current Liabilities 150.93b)
Debt / Equity = 0.16 (Debt 58.54b / totalStockholderEquity, last quarter 358.49b)
Debt / EBITDA = 0.49 (Net Debt 48.63b / EBITDA 98.49b)
Debt / FCF = 2.63 (Net Debt 48.63b / FCF TTM 18.47b)
Total Stockholder Equity = 339.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.82% (Net Income 58.62b / Total Assets 542.00b)
RoE = 17.25% (Net Income TTM 58.62b / Total Stockholder Equity 339.91b)
RoCE = 23.10% (EBIT 79.40b / Capital Employed (Equity 339.91b + L.T.Debt 3.80b))
RoIC = 16.09% (NOPAT 61.74b / Invested Capital 383.71b)
WACC = 7.21% (E(1036.68b)/V(1095.22b) * Re(7.55%) + D(58.54b)/V(1095.22b) * Rd(1.55%) * (1-Tc(0.22)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 123.5%
[DCF Debug] Terminal Value 77.86% ; FCFE base≈12.38b ; Y1≈12.03b ; Y5≈12.05b
Fair Price DCF = 257.5 (DCF Value 214.38b / Shares Outstanding 832.5m; 5y FCF grow -3.95% → 3.0% )
EPS Correlation: 16.15 | EPS CAGR: -42.65% | SUE: -2.34 | # QB: 0
Revenue Correlation: 49.78 | Revenue CAGR: 10.03% | SUE: 0.02 | # QB: 0

Additional Sources for RDY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle